Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361244346> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4361244346 abstract "<div>Abstract<p>The phosphoinositide 3-kinase (PI3K) pathway is a major target for cancer drug development. PI-103 is an isoform-selective class I PI3K and mammalian target of rapamycin inhibitor. The aims of this work were as follows: first, to use magnetic resonance spectroscopy (MRS) to identify and develop a robust pharmacodynamic (PD) biomarker for target inhibition and potentially tumor response following PI3K inhibition; second, to evaluate mechanisms underlying the MRS-detected changes. Treatment of human PTEN null PC3 prostate and <i>PIK3CA</i> mutant HCT116 colon carcinoma cells with PI-103 resulted in a concentration- and time-dependent decrease in phosphocholine (PC) and total choline (tCho) levels (<i>P</i> < 0.05) detected by phosphorus (<sup>31</sup>P)- and proton (<sup>1</sup>H)-MRS. In contrast, the cytotoxic microtubule inhibitor docetaxel increased glycerophosphocholine and tCho levels in PC3 cells. PI-103–induced MRS changes were associated with alterations in the protein expression levels of regulatory enzymes involved in lipid metabolism, including choline kinase α (ChoK<sub>α</sub>), fatty acid synthase (FAS), and phosphorylated ATP-citrate lyase (pACL). However, a strong correlation (r<sup>2</sup> = 0.9, <i>P</i> = 0.009) was found only between PC concentrations and ChoK<sub>α</sub> expression but not with FAS or pACL. This study identified inhibition of ChoK<sub>α</sub> as a major cause of the observed change in PC levels following PI-103 treatment. We also showed the capacity of <sup>1</sup>H-MRS, a clinically well-established technique with higher sensitivity and wider applicability compared with <sup>31</sup>P-MRS, to assess response to PI-103. Our results show that monitoring the effects of PI3K inhibitors by MRS may provide a noninvasive PD biomarker for PI3K inhibition and potentially of tumor response during early-stage clinical trials with PI3K inhibitors. Cancer Res; 70(13); 5507–17. ©2010 AACR.</p></div>" @default.
- W4361244346 created "2023-03-31" @default.
- W4361244346 creator A5003965204 @default.
- W4361244346 creator A5010949316 @default.
- W4361244346 creator A5040208664 @default.
- W4361244346 creator A5042056024 @default.
- W4361244346 creator A5048384848 @default.
- W4361244346 creator A5058014829 @default.
- W4361244346 creator A5062696393 @default.
- W4361244346 creator A5065401076 @default.
- W4361244346 date "2023-03-30" @default.
- W4361244346 modified "2023-10-14" @default.
- W4361244346 title "Data from The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy" @default.
- W4361244346 doi "https://doi.org/10.1158/0008-5472.c.6500205" @default.
- W4361244346 hasPublicationYear "2023" @default.
- W4361244346 type Work @default.
- W4361244346 citedByCount "0" @default.
- W4361244346 crossrefType "posted-content" @default.
- W4361244346 hasAuthorship W4361244346A5003965204 @default.
- W4361244346 hasAuthorship W4361244346A5010949316 @default.
- W4361244346 hasAuthorship W4361244346A5040208664 @default.
- W4361244346 hasAuthorship W4361244346A5042056024 @default.
- W4361244346 hasAuthorship W4361244346A5048384848 @default.
- W4361244346 hasAuthorship W4361244346A5058014829 @default.
- W4361244346 hasAuthorship W4361244346A5062696393 @default.
- W4361244346 hasAuthorship W4361244346A5065401076 @default.
- W4361244346 hasBestOaLocation W43612443462 @default.
- W4361244346 hasConcept C153911025 @default.
- W4361244346 hasConcept C184235292 @default.
- W4361244346 hasConcept C185592680 @default.
- W4361244346 hasConcept C190283241 @default.
- W4361244346 hasConcept C2776330855 @default.
- W4361244346 hasConcept C2776923060 @default.
- W4361244346 hasConcept C2778918659 @default.
- W4361244346 hasConcept C2780601828 @default.
- W4361244346 hasConcept C2781123555 @default.
- W4361244346 hasConcept C2781322055 @default.
- W4361244346 hasConcept C41625074 @default.
- W4361244346 hasConcept C55493867 @default.
- W4361244346 hasConcept C86554907 @default.
- W4361244346 hasConcept C86803240 @default.
- W4361244346 hasConceptScore W4361244346C153911025 @default.
- W4361244346 hasConceptScore W4361244346C184235292 @default.
- W4361244346 hasConceptScore W4361244346C185592680 @default.
- W4361244346 hasConceptScore W4361244346C190283241 @default.
- W4361244346 hasConceptScore W4361244346C2776330855 @default.
- W4361244346 hasConceptScore W4361244346C2776923060 @default.
- W4361244346 hasConceptScore W4361244346C2778918659 @default.
- W4361244346 hasConceptScore W4361244346C2780601828 @default.
- W4361244346 hasConceptScore W4361244346C2781123555 @default.
- W4361244346 hasConceptScore W4361244346C2781322055 @default.
- W4361244346 hasConceptScore W4361244346C41625074 @default.
- W4361244346 hasConceptScore W4361244346C55493867 @default.
- W4361244346 hasConceptScore W4361244346C86554907 @default.
- W4361244346 hasConceptScore W4361244346C86803240 @default.
- W4361244346 hasLocation W43612443461 @default.
- W4361244346 hasLocation W43612443462 @default.
- W4361244346 hasOpenAccess W4361244346 @default.
- W4361244346 hasPrimaryLocation W43612443461 @default.
- W4361244346 hasRelatedWork W1558705775 @default.
- W4361244346 hasRelatedWork W1640494480 @default.
- W4361244346 hasRelatedWork W1965990791 @default.
- W4361244346 hasRelatedWork W1975571564 @default.
- W4361244346 hasRelatedWork W1995477876 @default.
- W4361244346 hasRelatedWork W2004013202 @default.
- W4361244346 hasRelatedWork W2092874303 @default.
- W4361244346 hasRelatedWork W2154129829 @default.
- W4361244346 hasRelatedWork W2768787369 @default.
- W4361244346 hasRelatedWork W2949840475 @default.
- W4361244346 isParatext "false" @default.
- W4361244346 isRetracted "false" @default.
- W4361244346 workType "article" @default.